Log in


-0.01 (-0.15 %)
(As of 06/2/2020 04:00 PM ET)
Today's Range
Now: $6.51
50-Day Range
MA: $6.31
52-Week Range
Now: $6.51
Volume1,000 shs
Average Volume2,009 shs
Market Capitalization$145.99 million
P/E RatioN/A
Dividend YieldN/A
Biofrontera AG, a biopharmaceutical company, engages in the development and commercialization pharmaceutical products for the treatment of dermatological conditions and diseases caused primarily by exposure to sunlight that result in sun damage to the skin. Its principal product is Ameluz, a prescription drug for the treatment of actinic keratosis. The company also offers BF-RhodoLED lamp, a photodynamic therapy for lesion-directed and field-directed treatment of actinic keratosis; and Belixos over-the-counter line of skin care cosmetics products. In addition, it is developing Ameluz for the treatment of basal cell carcinoma; BF-derm1 for the treatment of chronic and antihistamine-resistant urticaria; and BF-1 for the prophylactic treatment of migraine. The company offers its products primarily in the United States and Europe. Biofrontera AG has a collaboration and partnership agreement with Maruho Co., Ltd. The company was founded in 1997 and is headquartered in Leverkusen, Germany.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.20 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:BFRA



Sales & Book Value

Annual Sales$35.02 million
Book Value$0.50 per share


Net Income$-8,240,000.00


Market Cap$145.99 million
Next Earnings Date8/25/2020 (Estimated)
OptionableNot Optionable

Receive BFRA News and Ratings via Email

Sign-up to receive the latest news and ratings for BFRA and its competitors with MarketBeat's FREE daily newsletter.

BIOFRONTERA AG/ADR (NASDAQ:BFRA) Frequently Asked Questions

How has BIOFRONTERA AG/ADR's stock been impacted by COVID-19 (Coronavirus)?

BIOFRONTERA AG/ADR's stock was trading at $9.28 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, BFRA shares have decreased by 29.8% and is now trading at $6.51. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of BIOFRONTERA AG/ADR?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BIOFRONTERA AG/ADR in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for BIOFRONTERA AG/ADR.

When is BIOFRONTERA AG/ADR's next earnings date?

BIOFRONTERA AG/ADR is scheduled to release its next quarterly earnings announcement on Tuesday, August 25th 2020. View our earnings forecast for BIOFRONTERA AG/ADR.

How were BIOFRONTERA AG/ADR's earnings last quarter?

BIOFRONTERA AG/ADR (NASDAQ:BFRA) posted its earnings results on Monday, April, 29th. The company reported ($0.18) EPS for the quarter, missing the consensus estimate of ($0.17) by $0.01. The company had revenue of $7.48 million for the quarter. BIOFRONTERA AG/ADR had a negative net margin of 34.52% and a negative return on equity of 64.65%. View BIOFRONTERA AG/ADR's earnings history.

How often does BIOFRONTERA AG/ADR pay dividends? What is the dividend yield for BIOFRONTERA AG/ADR?

BIOFRONTERA AG/ADR declared a -- dividend on Wednesday, March 18th. Investors of record on Thursday, March 19th will be paid a dividend of $0.0221 per share on Monday, March 30th. The ex-dividend date of this dividend is Wednesday, March 18th. View BIOFRONTERA AG/ADR's dividend history.

What price target have analysts set for BFRA?

2 brokerages have issued 1-year price objectives for BIOFRONTERA AG/ADR's stock. Their forecasts range from $8.00 to $11.00. On average, they expect BIOFRONTERA AG/ADR's stock price to reach $9.50 in the next twelve months. This suggests a possible upside of 45.9% from the stock's current price. View analysts' price targets for BIOFRONTERA AG/ADR.

Has BIOFRONTERA AG/ADR been receiving favorable news coverage?

News stories about BFRA stock have trended somewhat positive recently, according to InfoTrie. The research firm identifies negative and positive news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. BIOFRONTERA AG/ADR earned a news sentiment score of 2.0 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 6.0 out of 10, meaning that recent news coverage is somewhat likely to have an impact on the stock's share price in the near future. View the latest news aboutBIOFRONTERA AG/ADR.

Who are some of BIOFRONTERA AG/ADR's key competitors?

What other stocks do shareholders of BIOFRONTERA AG/ADR own?

Who are BIOFRONTERA AG/ADR's key executives?

BIOFRONTERA AG/ADR's management team includes the following people:
  • Prof. Hermann Lübbert, Co-Founder, Chairman of Management Board & CEO (Age 63)
  • Mr. Thomas Schaffer, CFO & Member of Management Board (Age 56)
  • Mr. Christoph Dünwald, Chief Commercial Officer, Head of Sales & Marketing and Additional Member of Management Board (Age 51)
  • Mr. Alexander Richardson, Head of UK Sales Team


(BFRA) raised $18 million in an initial public offering (IPO) on Wednesday, February 14th 2018. The company issued 1,500,000 shares at a price of $11.00-$13.00 per share. Benchmark served as the underwriter for the IPO and Dawson James Securities and Lake Street Capital Markets were co-managers.

What is BIOFRONTERA AG/ADR's stock symbol?

BIOFRONTERA AG/ADR trades on the NASDAQ under the ticker symbol "BFRA."

Who are BIOFRONTERA AG/ADR's major shareholders?

BIOFRONTERA AG/ADR's stock is owned by a number of retail and institutional investors. Top institutional investors include Sowell Financial Services LLC (0.20%).

Which major investors are buying BIOFRONTERA AG/ADR stock?

BFRA stock was purchased by a variety of institutional investors in the last quarter, including Sowell Financial Services LLC.

How do I buy shares of BIOFRONTERA AG/ADR?

Shares of BFRA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is BIOFRONTERA AG/ADR's stock price today?

One share of BFRA stock can currently be purchased for approximately $6.51.

How big of a company is BIOFRONTERA AG/ADR?

BIOFRONTERA AG/ADR has a market capitalization of $145.99 million and generates $35.02 million in revenue each year. BIOFRONTERA AG/ADR employs 149 workers across the globe.

What is BIOFRONTERA AG/ADR's official website?

The official website for BIOFRONTERA AG/ADR is www.biofrontera.com.

How can I contact BIOFRONTERA AG/ADR?

BIOFRONTERA AG/ADR's mailing address is HEMMELRATHER WEG 201, LEVERKUSEN 2M, D-51377. The company can be reached via phone at 011-49-2148-7600 or via email at [email protected]

This page was last updated on 6/3/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.